Fc Receptor (FcR)
Fc Receptor
Fc Receptors (FcR) are a class of cell surface receptors that can recognize and bind to the Fc region of immunoglobulins, playing an important role in processes such as the immune response and immune regulation. According to the types of immunoglobulins they recognize, FcR can be classified into FcγR, FcεR, FcαR, etc. According to their functional characteristics, they can be divided into activating FcR and inhibitory FcR. FcR mediate the phagocytosis of immune cells, prompting phagocytes to eliminate antigenic foreign substances such as pathogens. FcR also participate in ADCC, which activates NK cells and other cells to kill target cells, affecting the immune response. In addition, FcR can clear immune complexes and prevent them from depositing in tissues and triggering inflammation. Abnormal functions or dysregulated expressions of FcR can lead to autoimmune diseases and allergic diseases. In tumors, FcR are involved in both the immune escape of tumor cells and can serve as targets for immunotherapy[1][2].
All Product Categories
-
Fc Receptor (FcR) Related Products (71)
Related Products (71)
-
Anti-Rat FcRn heavy chain heterodimers Antibody (1G3)
0 ImagesCat. No.: HY-P990818Anti-Rat FcRn heavy chain heterodimers Antibody (1G3) is an anti-rat FcRn heavy chain heterodimers IgG1 monoclonal antibody. Anti-Rat FcRn heavy chain heterodimers Antibody (1G3) can effectively bind to FcRn and competitively inhibit the binding of IgG to FcRn. Anti-Rat FcRn heavy chain heterodimers Antibody (1G3) can reduce the total serum IgG level. Anti-Rat FcRn heavy chain heterodimers Antibody (1G3) can be used for researches on autoimmune conditions such as experimental autoimmune myasthenia gravis (EAMG). The recommend isotype control of Anti-Rat FcRn heavy chain heterodimers Antibody (1G3): Mouse IgG1 kappa, Isotype Control (HY-P99977).
-
GMA-161
0 ImagesCat. No.: HY-P991074
-
Trovostobart
0 ImagesSynonyms: KVA-12123; KVA-12.1
-
Valziflocept
0 ImagesSynonyms: BAX1810; TAK-752; SM101Valziflocept (BAX1810) is a recombinant soluble human FcγRIIb receptor that targets Fc and FcγR. FcγRs bind to and neutralize pathogenic IgG, thereby acting as a "decoy" or "scavenger" receptor that reduces the severity of autoimmune diseases. Valziflocept is used in research on autoimmune diseases such as systemic lupus erythematosus (SLE).
-
MGD010
0 ImagesCat. No.: HY-P991086Purity: 99.06%Synonyms: PRV-3279MGD010 (PRV-3279) is a bispecific antibody targeting CD32B (FcγRIIb) and CD79B. MGD010 transmits negative signals by simultaneously co-linking CD32B (FcγRIIb) with CD79B, a component of the B-cell receptor (BCR), thereby inhibiting activated B cells. MGD010 can be used in research related to autoimmune diseases.
-
AKIR001
0 ImagesCat. No.: HY-P991922Purity: 99.41%AKIR001 is a high-affinity human IgG1 antibody targeting CD44v6. AKIR001 carries LALA-silencing mutations in its FcγR-binding domain to reduce FcγR and C1q interactions, minimizing tissue interactions and limiting CDC and ADCC risks. [177Lu] radiolabeled AKIR001, namely [177Lu]Lu-AKIR001, has anticancer activity against epidermoid carcinoma.
-
Nebaprubart
0 ImagesCat. No.: HY-P991705CAS No.: 2911556-99-3Synonyms: JJP-1212
-
TAVO101
0 ImagesCat. No.: HY-P992474TAVO101 is a humanized anti-TSLP antibody with an EC50 of 0.19 nM against hTSLP. TAVO101 inhibits STAT5 activation and CCL17 release. TAVO101 carries Fc region mutations that enhance its binding to FcRn while reducing its binding to FcγRI, FcγRIIIA and C1q, thereby attenuating effector functions. TAVO101 reduces the levels of inflammatory markers, cell infiltration and histopathological damage in preclinical models of asthma, psoriasis and atopic dermatitis. TAVO101 can be used for research related to asthma, psoriasis and atopic dermatitis.
-
Mouse IgG Fc fragment
0 ImagesCat. No.: HY-NP0196D
-
Rabbit IgG Fab fragment
0 ImagesCat. No.: HY-NP0198B
-
Anti-Fc gamma R1 Antibody
0 ImagesCat. No.: HY-P990413The Anti-Fc gamma R1 Antibody is a human-derived antibody expressed in CHO, targeting Fc gamma R1. The Anti-Fc gamma R1 Antibody features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For the isotype control of the Anti-Fc gamma R1 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
-
VIR-2482
0 ImagesCat. No.: HY-P992482VIR-2482 is a monoclonal antibody targeting influenza A hemagglutinin (HA). VIR-2482 is generated by introducing LS mutations (M428L/N434S) into the Fc region of MEDI8852 (HY-P991446). VIR-2482 binds to the conserved HA stem epitope across all 18 influenza A HA subtypes, neutralizes a broad spectrum of H1N1 and H3N2 strains, binds to FcγRIIIa, FcγRIIa and C1q, and induces antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. VIR-2482 reduces morbidity and mortality caused by seasonal influenza A strains and provides prophylactic protection in mice. VIR-2482 can be used in research related to influenza A disease.
-
SYN1327
0 ImagesSYN1327 is a potent monomeric cyclic competitive antagonistic peptide targeting the neonatal Fc receptor (FcRn), with a Kd of 31 nM for human FcRn at pH 6 and a Kd of 170 nM at pH 7.4. SYN1327 competitively binds to the IgG-binding site of FcRn and inhibits the binding of human IgG to FcRn. SYN1327 acts as the monomeric precursor of the dimeric peptide SYN1436 (HY-P11882). SYN1327 can be used in studies related to IgG-mediated autoimmune diseases.
-
2′,3′-Dihydroxypuberulin
0 ImagesCat. No.: HY-N19733CAS No.: 79147-77-62′,3′-Dihydroxypuberulin is a naturally derived inhibitor of the FcεRI β-chain with FcεRI expression inhibitory activity in mast cells. 2′,3′-Dihydroxypuberulin suppresses the mRNA level of the FcεRI β-chain, blocks the assembly of the FcεRI tetramer, and reduces the cell surface expression level of FcεRI. 2′,3′-Dihydroxypuberulin can be used in studies related to type I allergic diseases.
-
SYN1753
0 ImagesCat. No.: HY-P12128SYN1753 is a selective inhibitor of human neonatal Fc receptor (hFcRn) with a Kd value of 0.5 μM. SYN1753 binds to the albumin-binding site of hFcRn, inhibits the hFcRn-albumin interaction, and thereby suppresses FcRn-mediated transcytosis of human albumin. SYN1753 can be used in studies related to acetaminophen-induced liver injury.
-
TNX-1500
0 ImagesCat. No.: HY-P991921TNX-1500 is a crystallizable fragment-modified anti-CD154 antibody. TNX-1500 contains the hu5c8 fragment antigen-binding (Fab) domain from Ruplizumab (HY-P99315) and an IgG4 Fc region engineered to reduce FcγRIIa binding. TNX-1500 has significantly weaker binding affinity to FcγRI, FcγRIIaH, FcγRIIbF, FcγRIIIaF, and FcγRIIIaV compared to hu5c8 (Kd values: 8.7 nM, 7100 nM, 4900 nM, 8000 nM, 6000 nM respectively). TNX-1500 prolongs nonhuman primate renal allograft survival, prolongs nonhuman primate cardiac allograft survival. TNX-1500 can be used for the research of allograft rejection[1][2].
-
Anti-CD32b/FCGR2B Antibody (2B6)
0 ImagesCat. No.: HY-P992211Anti-CD32b/FCGR2B Antibody (2B6) is a human monoclonal antibody targeting CD32B. Anti-CD32b/FCGR2B Antibody (2B6) can be used for research on B-cell lymphoma.
-
SYN1327 acetate
0 ImagesCat. No.: HY-P11786ASYN1327 acetate is a potent monomeric cyclic competitive antagonistic peptide targeting the neonatal Fc receptor (FcRn), with a Kd of 31 nM for human FcRn at pH 6 and a Kd of 170 nM at pH 7.4. SYN1327 acetate competitively binds to the IgG-binding site of FcRn and inhibits the binding of human IgG to FcRn. SYN1327 acetate acts as the monomeric precursor of the dimeric peptide SYN1436 (HY-P11882). SYN1327 acetate can be used in studies related to IgG-mediated autoimmune diseases.
